Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Cell Research

Volumn 27, Issue 1, 2017, Pages 147-150

  Na, Zhenkun ^a   Yeo, Siok Ping ^b   Bharath, Sakshibeedu R ^a   Bowler, Matthew W ^d   Balikçi, Esra ^a   Wang, Cheng I ^b   Song, Haiwei ^a,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; IMMUNITY; METABOLISM; MOUSE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNITY; LIGANDS; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84975226255     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2016.77     Document Type: Letter

References (10)

1. Pardoll DM. Nat Rev Cancer 2012; 12:252-264.
2. Okazaki T, Chikuma S, Iwai Y, et al. Nat Immunol 2013; 14:1212-1218.
3. Hamid O, Robert C, David A, et al. N Engl J Med 2013; 369:134-144.
4. Rivoltini L, Carrabba M, Huber V, et al. Immunol Rev 2002; 188:97-113.
5. Riley JL. N Engl J Med 2013; 369:187-189.
6. Lin DY, Tanaka Y, Iwasaki M, et al. Proc Natl Acad Sci USA 2008, 105:3011-3016.
7. Lazar-Molnar E, Yan Q, Cao E, et al. Proc Natl Acad Sci USA 2008; 105:10483-10488.
8. Zak KM, Kitel R, Przetocka S, et al. Structure 2015; 23:2341-2348.
9. Scapin G, Yang X, Prosise WW, et al. Nat Struct Mol Biol 2015; 22:953-958.
10. Cheng X, Veverka V, Radhakrishnan A, et al. J Biol Chem 2013; 288:11771-11785.